IRD — Opus Genetics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1228627 ·
Last close
$4.05
Market Cap
$391.45M
52W High
$7.07
52W Low
$1.70
ADV30
1,288,842
Next earnings
2026-11-10
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 755,000 — -16,480,000 -8,098,000 92,968,000 88,812,000 105,954,000
Mar 2026 2,157,000 — -14,364,000 -65,535,000 66,787,000 59,959,000 112,623,000
Dec 2025 3,865,000 — -11,453,000 -16,523,000 50,243,000 45,091,000 34,895,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-48,546,000
Investing CF
$-189,000
Financing CF
$106,994,000
CapEx
—
Dividends Paid
—
Buybacks
$-149,000
EPS Diluted TTM
$-1.54
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-308,717,000
Inventory
—
Receivables
$1,633,000
ST Investments
$0
EBIT TTM
$-134,071,000
Pretax Income TTM
$-136,651,000
Interest Exp TTM
$2,580,000
Analysts
17

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,914,000
EBITDA
$-61,482,000
Free Cash Flow
$-54,377,752
Enterprise Value
$331,591,264
Total Cash
$88,974,000
Total Debt
$35,881,000
Shares Out
96,654,336
Trailing EPS
$-1.48
Book Value
$0.40
ROE
-615.6%
ROA
-58.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 14,196,000 -38,599,000 -49,591,000 50,243,000 34,895,000 15,348,000 -35,253,000
Dec 2024 10,992,000 -34,074,000 -57,532,000 36,862,000 30,138,000 6,724,000 -25,576,000
Dec 2023 19,049,000 -10,563,000 -9,986,000 53,948,000 4,042,000 49,906,000 -1,112,000
Dec 2022 39,850,000 18,226,000 17,888,000 48,992,000 2,753,000 46,239,000 14,314,000

TTM Snapshot

Revenues TTM
$9,856,000
NetIncome TTM
$-107,610,000
OpCashFlow TTM
—
Assets (Latest)
$92,968,000
Forward EPS
$-0.76

Max Pain — expiry 2027-02-19

max pain strike: $5.00 · spot: $3.92 · call oi: 4,577 · put oi: 206
Expected Move to 2027-02-19: ±$2.90 (73.98%) — implied range $1.02 – $6.82 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RZLT Rezolute, Inc. $388.37M $4.01 —
ELTP ELITE PHARMACEUTICALS INC /NV/ $397.36M $0.37 —
PTCHF PureTech Health plc $405.77M $1.65 —
AVTX Avalo Therapeutics, Inc. $412.28M $7.13 —
CRMD CorMedix Inc. $371.44M $4.67 —

News headlines (Yahoo Finance, 1h cache)

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates
2026-11-10 12:25 · Yahoo
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
2026-11-10 12:00 · Yahoo
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
2026-11-05 12:00 · Yahoo
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
2026-11-03 12:00 · Yahoo
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
2026-10-29 11:00 · Yahoo
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
2026-10-25 12:02 · Yahoo
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
2026-10-21 11:00 · Yahoo
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
2026-10-16 17:58 · Yahoo
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
2026-10-16 16:00 · Yahoo
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
2026-10-15 20:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.